# psoriasis - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 6
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 3982
- Completion tokens: 17170
- Reasoning tokens: 
- Total tokens: 21152
- API requests reported: 
- Elapsed seconds: 157.625
- Final benchmark system: raw; file rank 5/5; original repeat 6; model vendor: DeepSeek

---
## 1. Overall biological interpretation

The input table is a psoriasis lesional-skin transcriptomic comparison. The statistical signals are extraordinarily strong: nearly all listed genes have very small FDRs, and the effect sizes are large—many are multi-log increases. The overall signature is not simply “inflammation” in the generic sense; it is a coordinated keratinocyte–immune circuit in which:

- **Keratinocyte-derived inflammatory amplifiers** are strongly activated: IL36A, IL36G, IL19, IL20, IL26.
- **Innate effector and alarmin genes** are massively induced: S100A7, S100A7A, S100A8, S100A12, DEFB4A/B, DEFB103A/B.
- **Epidermal differentiation and barrier remodelling genes** are shifted toward a regenerative, hyperproliferative phenotype: KRT6A, SPRR2 family, SPRR3, LCE3A/D, SERPINB3/4/11/13, GJB2/GJB6.
- **Lipid, eicosanoid, and tissue-remodelling genes** are co-upregulated: PLA2G4D/E, FABP5, HPSE, KLK13, PRSS27, TMPRSS11D.
- Downregulated genes are fewer, but include normal-epidermal metabolic markers such as CYP2W1, UGT3A2, and the EGFR ligand BTC, suggesting loss of normal keratinocyte metabolic/differentiation identity.

Thus, the transcriptome reflects a hyperplastic, metabolically reprogrammed epidermis interacting with innate and adaptive immune cells, with strong NF-κB/IL-36/IL-20/STAT3 signal integration.

---

## 2. Core biological programs

### Program 1: IL-36 and IL-20 family cytokine-driven inflammatory signalling  
**Direction:** Upregulated in lesional skin  
**Major supporting genes:** IL36A, IL36G, IL19, IL20, IL26, IL36RN, IRAK2, TNIP3, ZC3H12A, PRKCQ  
**Pathway:** Reactome “Interleukin-20 family signalling”; KEGG “Cytokine–cytokine receptor interaction”; Hallmark “IL6/JAK/STAT3 signalling”  
**Why collectively:** This is not a single cytokine; it is a cytokine family network. IL36A and IL36G are IL-1-superfamily agonists; IL19/IL20/IL26 belong to the IL-20 subfamily and signal through shared receptor subunits, with strong effects on keratinocyte proliferation and STAT3 activation. IRAK2 is downstream of IL-1R/TLR/IL-36 receptor signalling; TNIP3 and ZC3H12A are NF-κB/immune mRNA-regulatory feedback genes. The co-upregulation of agonists and regulators indicates an active, feedback-modulated proinflammatory circuit.  
**Strength and limitations:** Extremely high statistical confidence and multiple independent cytokine genes support this as a dominant program. However, the table does not show which cell types produce these cytokines, nor does it measure protein abundance or receptor activation.

---

### Program 2: Aberrant keratinocyte differentiation and cornified-envelope remodelling  
**Direction:** Upregulated  
**Major supporting genes:** SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR2G, SPRR3, LCE3A, LCE3D, KRT6A, GJB2, GJB6, SERPINB3, SERPINB4, SERPINB11, SERPINB13, PI3, TCN1, AKR1B10, AKR1B15, FABP5  
**Pathway:** Reactome “Keratinization”; “Formation of the cornified envelope”; GO “keratinocyte differentiation”  
**Why collectively:** Psoriasis is characterized by epidermal hyperplasia with abnormal differentiation. SPRRs and LCEs are components crosslinked into the cornified envelope; their coordinated upregulation indicates an activated epidermal differentiation program. KRT6A is a marker of hyperproliferative/activated keratinocytes; GJB2/GJB6 are connexins involved in keratinocyte communication; SERPINB3/B4 and PI3 are protease-inhibitor genes associated with epidermal barrier stress.  
**Strength and limitations:** This program is supported by many genes with very large fold changes. The limitation is that bulk skin RNA cannot distinguish whether the signal arises from increased keratinocyte numbers, altered differentiation, or both.

---

### Program 3: Alarmin, antimicrobial peptide, and neutrophil-associated innate response  
**Direction:** Upregulated  
**Major supporting genes:** S100A7, S100A7A, S100A8, S100A12, DEFB4A, DEFB4B, DEFB103A, DEFB103B, PI3, PLBD1, TCN1, CXCR2, HRH2  
**Pathway:** GO “antimicrobial humoral immune response”; Reactome “Neutrophil degranulation”  
**Why collectively:** S100 family proteins and β-defensins are major keratinocyte and neutrophil antimicrobial/alarmin molecules. S100A8 and S100A12 can act as DAMPs via TLR4/RAGE; β-defensins are antimicrobial peptides and chemoattractants; CXCR2 is a neutrophil chemokine receptor; TCN1 and PLBD1 are granule-associated genes. Together they are consistent with psoriasis histology, including epidermal neutrophil microabscesses.  
**Strength and limitations:** Multiple gene families converge on the same innate effector biology. The main limitation is that these genes are expressed by both keratinocytes and neutrophils, so cell-composition changes contribute significantly to the signal.

---

### Program 4: Immune-cell recruitment, T-cell/B-cell organization, and checkpoint modulation  
**Direction:** Upregulated  
**Major supporting genes:** CXCL13, CXCR2, ADAP2, CD274, PRKCQ, HRH2, PLA2G4D, PLA2G4E  
**Pathway:** KEGG “Chemokine signaling pathway”; GO “leukocyte chemotaxis”  
**Why collectively:** CXCL13 is a B-cell/T-follicular-helper-cell chemokine; CXCR2 is a neutrophil/myeloid chemokine receptor; ADAP2 is involved in immune-cell migration; PRKCQ is required for T-cell activation; CD274/PD-L1 is an immune-checkpoint ligand induced by inflammatory cytokines. This combination indicates an adaptive T/B-cell infiltrate with simultaneous inflammatory and counter-regulatory signals.  
**Strength and limitations:** The genes are biologically coherent, but the table does not show actual immune-cell abundance or spatial organization. CXCL13’s major receptor, CXCR5, is not in the input list, so the link is inferred from known biology.

---

### Program 5: Metabolic and tissue-remodelling reprogramming  
**Direction:** Upregulated, with some downregulated metabolic genes  
**Major supporting genes:** KYNU, AKR1B10, AKR1B15, FABP5, PLA2G4D, PLA2G4E, HPSE, KLK13, PRSS27, TMPRSS11D, ABCG4, SLC6A14; downregulated BTC, CYP2W1, UGT3A2  
**Pathway:** GO “tryptophan catabolic process”; GO “fatty acid metabolic process”; Reactome “Heparan sulfate/heparin degradation”; GO “proteolysis”  
**Why collectively:** KYNU is a tryptophan/kynurenine pathway enzyme, which can modulate T-cell responses; AKR1B10/15 are aldo-keto reductases involved in lipid/retinoid handling; FABP5 transports fatty acids and cooperates with PPAR/retinoid signalling; PLA2G4D/E generate arachidonic acid and lysophospholipids; HPSE degrades heparan sulfate and releases growth factors; KLK13, PRSS27, and TMPRSS11D are extracellular proteases. Downregulation of CYP2W1 and UGT3A2 suggests loss of normal keratinocyte xenobiotic/metabolic functions.  
**Strength and limitations:** This is a coherent secondary program, but it is broad and may partly reflect proliferation-associated metabolic rewiring rather than a single disease-specific pathway.

---

## 3. Key genes and interaction modules

The following modules are prioritized because they are statistically strong and biologically interpretable.

### 1. IL36A / IL36G / IL36RN module  
- **Direction:** All upregulated; IL36A log2FC = 11.37, IL36G = 5.68, IL36RN = 3.00  
- **Role:** Central IL-36 axis. IL36A/G activate IL-36 receptor signaling; IL36RN encodes the receptor antagonist IL-36Ra.  
- **Relationship type:** Ligand–receptor/antagonist pathway co-membership. IL36RN product directly competes for the IL-36 receptor, but this is not evidence of direct physical interaction between the IL36A/G and IL36RN genes.  
- **Interpretation:** The simultaneous upregulation of agonists and an antagonist suggests active IL-36 pathway engagement with negative feedback.

### 2. IL19 / IL20 / IL26 module  
- **Direction:** All upregulated  
- **Role:** IL-20 subfamily cytokines; promote keratinocyte proliferation, STAT3 activation, and inflammatory gene expression.  
- **Relationship type:** Pathway co-membership; they share receptor subunits.  
- **Interpretation:** This is a keratinocyte-immune amplification loop often downstream of IL-17/IL-23 in psoriasis.

### 3. S100 alarmin / β-defensin module  
- **Genes:** S100A7, S100A7A, S100A8, S100A12, DEFB4A/B, DEFB103A/B  
- **Direction:** All strongly upregulated  
- **Role:** Antimicrobial peptides and damage-associated molecular patterns; promote innate immune activation and neutrophil chemotaxis.  
- **Relationship type:** Co-expression and functional co-membership in the antimicrobial/alarmin response. No direct physical interaction is inferred between S100 and defensin proteins from this dataset.  
- **Interpretation:** This module marks an intensely activated innate barrier response.

### 4. SPRR / LCE / KRT6A cornified-envelope module  
- **Genes:** SPRR2A/B/D/E/G, SPRR3, LCE3A/D, KRT6A  
- **Direction:** Upregulated  
- **Role:** Aberrant keratinocyte differentiation and cornified-envelope remodeling.  
- **Relationship type:** Pathway co-membership; SPRR and LCE proteins are crosslinked by transglutaminases into the cornified envelope. This is a biochemical/substrate relationship, not a gene-regulatory interaction.  
- **Interpretation:** Reflects the regenerative, abnormal differentiation program of psoriatic epidermis.

### 5. SERPINB / PI3 protease-inhibitor module  
- **Genes:** SERPINB3, SERPINB4, SERPINB11, SERPINB13, PI3  
- **Direction:** Upregulated  
- **Role:** Protection against excessive protease activity, epidermal barrier stress, and protease-mediated inflammation.  
- **Relationship type:** Gene-family/pathway co-membership; functional redundancy likely.  
- **Interpretation:** Supports the view that lesional skin is undergoing protease–antiprotease imbalance.

### 6. PLA2G4D / PLA2G4E / FABP5 lipid signalling module  
- **Direction:** Upregulated  
- **Role:** Phospholipase A2 enzymes release arachidonate/eicosanoid precursors; FABP5 transports fatty acids and can amplify inflammatory lipid signaling.  
- **Relationship type:** Functional/pathway overlap, not direct physical interaction.  
- **Interpretation:** Suggests active eicosanoid and lipid-mediator production in lesional skin.

### 7. KYNU / AKR1B10 / AKR1B15 metabolic module  
- **Direction:** Upregulated  
- **Role:** Tryptophan/kynurenine metabolism and carbonyl/retinoid/lipid metabolism.  
- **Relationship type:** Co-expression of metabolic enzymes; likely pathway overlap rather than direct interaction.  
- **Interpretation:** Indicates metabolic reprogramming that may influence local T-cell and keratinocyte behavior.

### 8. CXCL13 / CXCR2 / CD274 / PRKCQ immune module  
- **Direction:** Upregulated  
- **Role:** Chemokine-mediated immune-cell recruitment, T-cell activation, and checkpoint signaling.  
- **Relationship type:** Co-expression in the inflammatory microenvironment. CXCL13’s main receptor is CXCR5, which is not in the dataset; CXCR2 binds other chemokines; CD274 binds PD-1; PRKCQ is downstream of T-cell receptor signaling. These are not direct molecular interactions with each other.  
- **Interpretation:** This module indicates a mixed innate/adaptive immune infiltrate with potential regulatory/checkpoint counterbalance.

### 9. HPSE / KLK13 / PRSS27 / TMPRSS11D tissue-remodelling module  
- **Direction:** Upregulated  
- **Role:** Heparan sulfate degradation and extracellular proteolysis; supports leukocyte trafficking, growth-factor release, and matrix remodelling.  
- **Relationship type:** Functional co-membership in proteolysis/extracellular-matrix remodelling.  
- **Interpretation:** Connects inflammation to tissue destruction and remodelling.

### 10. Downregulated normal-epidermal / metabolic module  
- **Genes:** BTC, CYP2W1, UGT3A2, SAPCD1, WAKMAR1  
- **Direction:** Downregulated  
- **Role:** BTC is an EGFR ligand; CYP2W1 and UGT3A2 are metabolic enzymes; their downregulation may reflect loss of normal keratinocyte differentiation/metabolic identity.  
- **Relationship type:** Likely co-downregulation due to shared cell-state change, not direct regulatory interaction. Caution is needed because some of these genes are poorly annotated.  
- **Interpretation:** This module may represent suppression of normal epidermal programs during hyperproliferative disease.

---

## 4. Validation priorities

### Priority 1: Mechanistic hypothesis — IL-36/IL-20 cytokines drive downstream S100/SPRR/alarmin expression  
- **Classification:** Mechanistic hypothesis  
- **Why:** These cytokines are at the top of the inflammatory hierarchy in the data and are clinically relevant in psoriasis-spectrum disease.  
- **Current evidence:** Strong co-upregulation of IL36A/G, IL19/20/26, and downstream keratinocyte/innate genes.  
- **External evidence:** IL-36 is strongly linked to pustular psoriasis; IL-20-family cytokines are reported to promote keratinocyte proliferation and STAT3 activation.  
- **Next step:** Use 3D keratinocyte/organotypic skin models with IL-36 or IL-20 pathway stimulation or blockade, then measure S100/SPRR/DEFB expression.  
- **Conclusion:** Supported hypothesis, not established causality.

### Priority 2: Therapeutic target — PLA2G4D/eicosanoid and/or HPSE axis  
- **Classification:** Therapeutic target  
- **Why:** Identifies potentially targetable lipid-mediator and ECM-remodelling nodes beyond classical cytokine pathways.  
- **Current evidence:** PLA2G4D/E, FABP5, and HPSE are strongly upregulated in lesional skin.  
- **External evidence:** Eicosanoids are known inflammatory mediators; heparinase inhibitors are being explored in inflammatory diseases. However, the existence of inhibitors does not by itself prove efficacy in psoriasis.  
- **Next step:** Test genetic or pharmacological inhibition in imiquimod-induced psoriasis models or human skin explants.  
- **Conclusion:** Exploratory hypothesis.

### Priority 3: Biomarker — S100A7/S100A12/DEFB4A/SPRR2A as disease-activity markers  
- **Classification:** Biomarker  
- **Why:** These genes show very large effect sizes and encode secreted or surface-detectable proteins.  
- **Current evidence:** Extremely high log2FC and very low FDR in lesional skin.  
- **External evidence:** S100 proteins, especially S100A8/A9, are already associated with psoriasis and psoriatic arthritis activity.  
- **Next step:** Validate in an independent psoriasis cohort; correlate with PASI, lesion severity, and serum/tape-strip protein levels.  
- **Conclusion:** Supported hypothesis.

### Priority 4: Interaction/network hypothesis — Alarmins, CXCR2 neutrophils, and PLA2 lipid mediators form an amplification loop  
- **Classification:** Interaction / network hypothesis  
- **Why:** Could explain the neutrophil-rich pathology of psoriasis and identify new combination targets.  
- **Current evidence:** Co-upregulation of S100/defensins, CXCR2, PLA2G4D/E, and lipid-metabolism genes in bulk tissue.  
- **External evidence:** S100 proteins and defensins are chemoattractants; CXCR2 ligands recruit neutrophils; eicosanoids amplify inflammation.  
- **Next step:** Use spatial transcriptomics, co-culture of keratinocytes and neutrophils, and CXCR2/PLA2 inhibition experiments.  
- **Conclusion:** Exploratory hypothesis.

### Priority 5: Confounding or composition check — Cell-composition differences between lesional and normal skin  
- **Classification:** Confounding or composition check  
- **Why:** Bulk skin RNA reflects keratinocyte hyperplasia, T-cell infiltration, and neutrophil microabscesses; some of the signal may reflect cell abundance rather than per-cell expression changes.  
- **Current evidence:** The dataset is bulk differential expression; many of the top genes are known keratinocyte or neutrophil markers.  
- **External evidence:** Psoriasis histology is well known to include epidermal acanthosis, T-cell infiltrates, and neutrophils.  
- **Next step:** Perform single-cell RNA-seq, spatial transcriptomics, flow-sorted populations, or digital deconvolution to assign genes to specific cell types.  
- **Conclusion:** Established limitation and a required validation step.

---

## 5. Evidence grounding

The major evidence sources are:

- **Direct evidence from the input dataset:** Differential expression direction, log2FC, P value, and FDR. This evidence is statistically strong but is limited to mRNA abundance in bulk tissue.
- **Pathway/ontology evidence:** The assignment of genes to inflammatory, keratinization, antimicrobial, chemokine, and metabolic pathways is based on known curated biology, not on a pathway-enrichment calculation performed here.
- **Protein interaction/regulatory evidence:** For IL36RN and IL-36 receptor, or SPRR/LCE transglutaminase crosslinking, there is known biochemical evidence. For most other gene pairs, only co-expression or pathway co-membership is claimed.
- **Disease-association evidence:** Many genes (S100A7, IL36A, DEFB4, SERPINB3/4, KRT6A) have been reported in psoriasis skin before. This is external supportive evidence, but it overlaps substantially with pathway/ontology knowledge.
- **Drug/therapeutic evidence:** IL-17/IL-23 blockade is clinically effective in psoriasis, and IL-36 blockade is relevant to pustular psoriasis. This supports the broader cytokine-centric interpretation but is not proof that any single gene in the table is a valid therapeutic target.
- **Genetic/clinical evidence:** Mutations in IL36RN cause generalized pustular psoriasis; this strongly supports the IL-36 pathway’s disease relevance. This is independent of the expression data.

Where multiple evidence sources align, they are partly independent, but pathway databases and literature often derive from the same underlying experiments. Functional validation remains necessary.

---

## 6. Limitations and alternative explanations

### 1. Bulk tissue cell-composition differences  
Lesional skin contains hyperplastic keratinocytes, T cells, neutrophils, dendritic cells, and altered fibroblasts. Normal skin does not. Many signals may reflect cell abundance rather than per-cell transcriptional change.  
**How to test:** scRNA-seq, spatial transcriptomics, immunohistochemistry, or deconvolution.

### 2. Disease severity, lesion site, stage, and treatment exposure are unknown  
Psoriasis plaques vary by location, chronicity, and prior topical/systemic therapy. The input data lack clinical metadata. This may affect the magnitude and composition of the transcriptomic signal.

### 3. Pathway redundancy and overlapping gene sets  
Several programs share genes or biological functions. For example, S100/defensin genes are both antimicrobial and inflammatory; SPRR/SERPIN genes are both differentiation and protease-protection related. This reduces the independence of “programs.”

### 4. Association versus causation / feedback ambiguity  
Upregulation of IL36RN, TNIP3, and ZC3H12A suggests active negative feedback, not just proinflammatory activation. Without perturbation experiments, causal direction cannot be assigned. The presence of a drug target does not prove therapeutic relevance.

### 5. Technical/annotation uncertainty for uncharacterized loci  
The table includes many poorly annotated loci, pseudogenes, and lncRNAs (e.g., VNN3P, CERNA2, LOC105376238, WAKMAR1, LINC02660) with extreme fold changes. Some may be real regulatory RNAs; others may be mapping artifacts or uncharacterized transcriptional noise. Independent validation with isoform-aware quantification or orthogonal methods is needed before assigning biological meaning.

---

## Summary

The psoriatic lesional transcriptome is dominated by a highly coordinated, multi-program inflammatory response: IL-36/IL-20 cytokine signalling, aberrant keratinocyte differentiation, alarmin/antimicrobial peptide production, immune-cell recruitment, and metabolic/tissue remodelling. The statistical evidence is extremely strong, but the biological interpretation remains hypothesis-generating without protein-level, cell-type-resolved, and functional validation. The most defensible conclusion is that this dataset reflects a severe, active psoriatic epidermal–immune circuit with strong evidence for IL-36/IL-20 and keratinocyte-derived innate effector involvement.
